Anti-retroviral (ARV) drug resistance in patients with second therapeutic failure in an HIV program, Colombia Resistencia a medicamentos Anti-rretrovirales (ARV) en pacientes con segundo fracaso terapéutico en un programa de VIH, Colombia

Abstract

Objective. To make a description of ARV drugs in patients with second therapeutic failure in an HIV Program between January and December, 2011. Materials and methods. Adescriptive, retrospective case series study was conducted. It was made a description of HIV mutations, clinical characteristics and laboratory findings of patients with resistance in second therapeutic failure. Results. 30 patients with second therapeutic failure were identified in the study period. The average time of use of ARV therapy per patient was 77.2 (SD = 56). 12 patients underwent three changes of ARV months shema per therapeutic failure and 2 other patients up to four changes of schema. Most frequent mutations were the primary to Protease inhibitors (M46I, I54V, L101) and to inhibitors of Reverse analog Transcriptase of Nucleoside. (Abacavir, Didanosine and Zidovudine, Stavudine).